| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/17/2009 | US20090232853 Treatment of laminitis |
| 09/17/2009 | US20090232812 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/17/2009 | US20090232809 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/17/2009 | US20090232772 Human corneal endothelial cell-derived precursor cells, cellular aggregates, methods for manufacturing the same, and methods for transplanting precursor cells and cellular aggregates |
| 09/17/2009 | CA2732764A1 Methods and compositions for treating inflammation and inflammation-related pathologies |
| 09/17/2009 | CA2718161A1 Drug delivery to the anterior and posterior segments of the eye using eye drops |
| 09/17/2009 | CA2717660A1 Therapy for disorders of the proximal digestive tract |
| 09/17/2009 | CA2717322A1 Apoaequorin-containing compositions and methods of using same |
| 09/17/2009 | CA2716724A1 Novel dosage and formulation |
| 09/17/2009 | CA2716723A1 Novel dosage and formulation |
| 09/17/2009 | CA2715982A1 Methods of treating hyperacidic disorders |
| 09/16/2009 | EP2100615A1 Cancer therapy |
| 09/16/2009 | EP2100600A1 Extended release oral dosage composition |
| 09/16/2009 | EP2100599A1 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 09/16/2009 | EP2100598A1 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 09/16/2009 | EP2100593A1 Ternary mixtures with increased collagen synthesis |
| 09/16/2009 | EP2100139A2 Biologically active compositions, methods for producing the same and biological applications |
| 09/16/2009 | EP2099492A2 Duloxetine composition |
| 09/16/2009 | EP2099451A2 Combination of an hdac inhibitor and an antimetabolite |
| 09/16/2009 | EP2099442A1 Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| 09/16/2009 | EP1564210B1 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
| 09/16/2009 | EP1523471B1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 09/16/2009 | EP1399479B1 Cation conducting gaba a receptors and their use |
| 09/16/2009 | EP1349568B1 Immunomodulatory constructs and their uses |
| 09/16/2009 | EP1027443B1 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 09/16/2009 | CN101534852A Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| 09/16/2009 | CN101534823A Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 09/16/2009 | CN101530618A Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma |
| 09/16/2009 | CN101530617A Pharmaceutical composition containing PPAR regulator and strontium salt |
| 09/16/2009 | CN100540058C Use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
| 09/16/2009 | CN100540054C Purpose of a medicine composition in preparing medicament for enhancing effect of radiation therapy and chemotherapy |
| 09/16/2009 | CN100540010C Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 09/16/2009 | CN100540007C Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
| 09/16/2009 | CN100540001C Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 09/15/2009 | US7589232 5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid; inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglycerimia |
| 09/15/2009 | US7589180 Specific binding proteins and uses thereof |
| 09/15/2009 | US7589124 Antiinflammatory agents; antipyretics; analgesics; 2,3-bis(nitroxy)-4-(2-(2-((2-chloro-6-fluorophenyl)amino)5-methylphenyl)acetyloxy)butyl 2-(2-((2-chloro-6-fluorophenyl)amino)5-methylphenyl)acetate; gastrointestinal disorders, wound healing, cardiovascular disorders |
| 09/15/2009 | US7589097 Using compounds such as 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine for therapy of Parkinson's disease; adenosine receptor antagonist; antidepressant, neurodegenerative disorders, cognition activator, attention deficit disorder |
| 09/15/2009 | US7589084 Anticancer compositions, and methods of making and using the same |
| 09/15/2009 | US7589080 β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
| 09/15/2009 | US7589075 e.g., an N6-benzyladenosine-5'-uronamide |
| 09/15/2009 | US7589069 Replication-competent anti-cancer vectors |
| 09/15/2009 | US7588785 Methods and kits for reducing cellular damage, inhibiting free radical production and scavenging free radicals |
| 09/15/2009 | US7588781 oral administering a mixture powders comprising a dissolved whey protein to increase release the bioactive carotenoid, polyphenol, vitamins, flavonoid, isoflavone, ceramide |
| 09/15/2009 | US7588768 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 09/15/2009 | US7588764 Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles |
| 09/15/2009 | US7588760 Binds to a denatured collagens but not to native triple helical forms of the collagen; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists |
| 09/15/2009 | CA2463583C Highly compressible ethylcellulose for tableting |
| 09/15/2009 | CA2429220C Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 09/15/2009 | CA2421683C Microparticles for delivery of the heterologous nucleic acids |
| 09/15/2009 | CA2415065C Oral compositions comprising host-response modulating agent |
| 09/15/2009 | CA2411233C Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 09/15/2009 | CA2408417C Local anesthetic methods and kits |
| 09/15/2009 | CA2407754C Prodrugs of hiv replication inhibiting pyrimidines |
| 09/15/2009 | CA2406562C Hiv replication inhibiting pyrimidines and triazines |
| 09/15/2009 | CA2349724C Silane copolymer coatings |
| 09/15/2009 | CA2270423C Prophylactic/therapeutic agent |
| 09/15/2009 | CA2156272C Dna encoding a human neuropeptide y/peptide yy/pancreatic polypeptide receptor (y4) and uses thereof |
| 09/15/2009 | CA2148871C Method of preventing hyperproliferative vascular disease |
| 09/11/2009 | WO2009111739A2 Treatment of herpes virus related diseases |
| 09/11/2009 | WO2009111648A1 Compositions and methods for mucositis and oncology therapies |
| 09/11/2009 | WO2009110816A1 Pharmaceutical composition based on hepatoprotector and prebiotic, the production and use thereof |
| 09/11/2009 | WO2009110416A1 Concomitant drug |
| 09/11/2009 | WO2009110415A1 Concomitant drug |
| 09/11/2009 | WO2009110383A1 Method for screening of therapeutic agent for cancer |
| 09/11/2009 | WO2009110351A1 Transdermally absorbable preparation |
| 09/11/2009 | WO2009110235A1 Combined use of cholestanol derivative |
| 09/11/2009 | WO2009110041A1 Cancer therapeutic agent by agent for cancer-specific introduction of prostacyclin receptor antagonist |
| 09/11/2009 | WO2009109605A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/11/2009 | WO2009109334A1 (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
| 09/11/2009 | WO2009089635A9 Treating neurodegenerative diseases with progranulin (pgrn) |
| 09/11/2009 | WO2009047826A3 Pharmaceutical composition comprising sucralphate and mesalazine |
| 09/11/2009 | CA2753844A1 Compositions and methods for mucositis and oncology therapies |
| 09/11/2009 | CA2717135A1 Combined use of cholestanol derivative |
| 09/11/2009 | CA2716851A1 Combination therapy with c-met and egfr antagonists |
| 09/11/2009 | CA2716518A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/10/2009 | US20090228998 Induction of exon skipping in eukaryotic cells |
| 09/10/2009 | US20090228997 Extracellular novel RAGE binding protein ( EN-RAGE) and uses thereof |
| 09/10/2009 | US20090227802 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| 09/10/2009 | US20090227692 Biomarkers for breast cancer |
| 09/10/2009 | US20090227662 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 09/10/2009 | US20090227608 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 09/10/2009 | US20090227564 Drug for prevention and/or therapy of endometriosis |
| 09/10/2009 | US20090227558 Amino-derivatives as novel inhibitors of histone deacetylase |
| 09/10/2009 | US20090227547 Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative |
| 09/10/2009 | US20090227530 Sodium channel blockers |
| 09/10/2009 | US20090227511 Methods and compositions for treating lesions of the respiratory epithelium |
| 09/10/2009 | US20090227501 Agents for preventing and/or treating upper digestive tract disorders |
| 09/10/2009 | US20090226518 (monitoring only) combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night |
| 09/10/2009 | US20090226491 Water-based delivery systems |
| 09/10/2009 | US20090226460 Compositions and methods for the treatment of disease |
| 09/10/2009 | US20090226425 Diagnostics and Therapeutics For Glaucoma |
| 09/10/2009 | US20090226415 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 09/10/2009 | US20090226407 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 09/10/2009 | US20090226403 Olfactory and pheromones G-protein coupled receptors |
| 09/10/2009 | US20090226400 Continuous delivery methods for treating hepatitis virus infection |
| 09/10/2009 | US20090226392 Phosphate-Binding Polymers for Oral Administration |
| 09/09/2009 | EP2098598A1 Screening method for prophylactic and/or therapeutic agent for disease accompanied by hepatitis c |
| 09/09/2009 | EP2098248A1 Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases |
| 09/09/2009 | EP2098247A2 Prevention and treatment of androgen-deprivation induced loss of BMD or bone fractures |